VANCOUVER, Oct. 17, 2017 /CNW/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today additional pre-clinical results in the development of INM-405 for the treatment of pain.
In recent pre-clinical testing, InMed employed several methods to verify the effects of individual, non-THC (tetrahydrocannabinol, the primary psychoactive ingredient in cannabis) cannabinoids, as well as a matrix of cannabinoid combinations, delivered to treat peripheral pain:
- in vivo animal models of pain to measure the pain tolerance;
- in vivo electrophysiology recordings to measure the blockage of pain signal transmission in the peripheral nerve fibres; and
- in vivo behavioral studies to verify the central nervous system (CNS) related side effects.
Results from these studies suggest that peripheral application of certain cannabinoid compounds, alone or in combination, is effective in the treatment of craniofacial muscle pain disorders, without any observed CNS side effects, and may be a more desirable strategy than systemic pain-relief administration. Previously, InMed reported (NR August 20, 2015) the expression of both CB1 and CB2 receptors in trigeminal ganglion neurons innervating the masseter muscle, providing evidence that these receptors can be targets for craniofacial muscle pain. CB1 and CB2 receptors are primary targets in the human body for cannabinoid drugs.
There is a need to find alternatives to treat chronic and severe pain that are non-addictive and have limited side effects. InMed continues to research the potential of non-THC cannabinoids to treat pain using a topical formulation. InMed's proof of concept study results published earlier this year in the European Journal of Pain (NR July 27, 2017) highlighted the topical application of THC to successfully treat peripheral pain.
Recently, InMed filed a provisional patent application in the United States for INM-405 and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, which is an important step in protecting the Company's intellectual and commercial property. The foundation of this patent is the unreported data, cited above, on non-THC cannabinoids and their ability to modulate pain. The patent cites a range of cannabinoids, alone or in combination, applied topically to treat various types of pain - muscle, nerve, arthritis-induced joint pain, etc.
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: that peripheral or topical application of cannabinoids targeting the natural endocannabinoid receptor system (in this case, receptor CB1) provides a valuable approach in treating chronic and/or acute severe pain without central side effects, InMed's proprietary bioinformatics database assessment tool, linking specific cannabinoids to diseases with a high unmet medical need, being able to validate the role of this class of compounds in a wide range of diseases, and the expected fundamental value drivers of the Company.
With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: demand for InMed's products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: that peripheral or topical application of cannabinoids, identified by InMed's proprietary bioinformatics database assessment tool, will be able to effectively target the natural endocannabinoid receptor system (in this case, receptor CB1) which will provide a valuable approach in treating chronic and/or acute severe pain without central side effects; InMed's proprietary platform technology, product pipeline and drug development programs may not return their expected level of value.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed's Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com. In addition, readers should review the disclosure under the heading "Risk Factors" in the Final Prospectus, once filed. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE InMed Pharmaceuticals Inc.
For further information: InMed Pharmaceuticals Inc., Chris Bogart, Investor Relations, T: 604.669.7207, E: [email protected]